The use of Intravenous Pentamidine as Prophylaxis against Pneumocystis Carinii Pneumonia in Patients with HIV Infection

Abstract

The purpose of this study is to report on the use of monthly intravenous pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) within a central London HIV unit.

A retrospective case note analysis of HIV-seropositive individuals using intravenous pentamidine as PCP prophylaxis was carried out. Aspects examined included reasons for using the regimen, compliance, adverse reactions and episodes of PCP. Eight patients were studied. There was no prophylaxis failure in 5 patients. Three patients developed PCP whilst on the regimen, although their compliance was poor.

In patients who are intolerant of established prophylaxis regimens, intravenous pentamidine may be a useful alernative. It is well tolerated, although compliance is the main problem. Further prospective studies are indicated to assess its efficacy.

Keywords

HIV pentamidine prophylaxis

Get full access to this article

View all access options for this article.

References

Multicenter AIDS Cohort Study Group. The risk of Pneumocystis carinii pneumonia among men infected with HIV. N Engl J Med 1990;322:161–5.

Abel

Castellano

Nettleman

MD.

Cost and benefit of secondary prophylaxis for PCP. JAMA 1991;266:6.

US Public Health Task Force. Recommendations for prophylaxis against PCP for persons infected with HIV. J Acauir Immune Def Syndr 1993;6(1):46–55.

Gazzard

BG.

Pentamidine. Br J Clin Pract 1989;43(5):153–7.

Martinez

Soriano

Gonzalez-Lahoz

Prophylaxis of Pneumocystis carinii pneumonia. AIDS 1993;7(8):1133–4.

Cheung

Marta

Niebert

Intramuscular pentamidine for the prevention of Pneumocystis carinii infection in patients with HIV. Clin Inf Dis 1993;16(1):22–5.

Wiewora

Rosado

Inks

DB.

Breakthrough PCP with combined aerosolised and intravenous pentamidine. IX International Conference on AIDS 1993 Abstract No. PO-B10–1450.